西藏药业：拟1.7亿-2亿元回购股份用于激励计划

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with an amount between 170 million and 200 million yuan, at a price not exceeding 55 yuan per share [1] Group 1: Share Repurchase Details - The repurchase is expected to involve 3,090,909 to 3,636,364 shares, representing 0.96% to 1.13% of the total share capital [1] - The funding for the repurchase will come from the company's own funds [1] - The repurchased shares will be used for equity incentives or employee stock ownership plans, and any shares not transferred within three years will be canceled [1] Group 2: Timeline and Impact - The repurchase will take place within 12 months from the board's approval [1] - The company's directors, supervisors, and controlling shareholders have no plans to reduce their holdings in the next three to six months [1] - The company believes that the repurchase will not have a significant impact on its operations [1]